Skip to main
FHTX
FHTX logo

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics (FHTX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Foghorn Therapeutics Inc demonstrates a strong potential for stock growth, primarily due to the promising advancements in its lead candidate, FHD-286, which exhibits significant mutational activity in acute myeloid leukemia (AML) and has shown favorable efficacy markers in heavily pretreated patient populations. Additionally, the company’s progress in its EP300 and CBP programs, with ongoing IND studies and preclinical data supporting their safety and effectiveness, positions Foghorn therapeutics to capitalize on innovative treatment strategies in oncology. Furthermore, the successful IND clearance for FHD-909 and the planned Phase 1 study initiation highlight an expanding pipeline, which enhances the company's ability to meet diverse cancer treatment needs and increase its market viability.

Bears say

Foghorn Therapeutics Inc reported a net loss of $22.9 million for the second quarter of 2024, a reduction from the $29.4 million loss recorded in the same quarter of the previous year, highlighting ongoing financial challenges despite slightly improved performance. The development of key drug candidates, FHD-286 and FHD-609, remains fraught with uncertainties, particularly surrounding the potential inefficacy of FHD-286 and possible safety concerns that could halt its progression. Additionally, considerable risks persist related to clinical and regulatory setbacks, as well as the company's ability to meet future sales projections, which contribute to a generally negative outlook for Foghorn's stock performance.

Foghorn Therapeutics (FHTX) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Foghorn Therapeutics (FHTX) Forecast

Analysts have given Foghorn Therapeutics (FHTX) a Buy based on their latest research and market trends.

According to 10 analysts, Foghorn Therapeutics (FHTX) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Foghorn Therapeutics (FHTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.